{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(1)"],"submitter":["Rizzo A"],"pubmed_abstract":["Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65−0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5−0.84; p < 0.001). In addition, imm"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["749-757"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9858216"],"repository":["biostudies-literature"],"pubmed_title":["Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis."],"pmcid":["PMC9858216"],"pubmed_authors":["Ricci AD","De Luca R","Rizzo A","Fanizzi A","Massafra R","Brandi G"],"additional_accession":[]},"is_claimable":false,"name":"Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis.","description":"Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65−0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5−0.84; p < 0.001). In addition, imm","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-08-16T03:06:33.818Z","creation":"2025-04-05T19:51:44.586Z"},"accession":"S-EPMC9858216","cross_references":{"pubmed":["36661706"],"doi":["10.3390/curroncol30010057"]}}